-

09:38:10 AM

KRYS Stock News

KRYS - Krystal Biotech Inc

08/01/22 6:39 PM

Nasdaq : KRYS

clinical triallow float

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy,

RHEA-AI

neutral

08/01/22 7:00 AM

Nasdaq : KRYS

clinical triallow float

Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy,

RHEA-AI

neutral

07/06/22 7:00 AM

Nasdaq : KRYS

conferenceslow float

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the William Blair Biotech Focus Conference 2022 taking place in New York from July 12-13. Krish Krishnan,

RHEA-AI

neutral

06/22/22 7:00 AM

Nasdaq : KRYS

low float

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene

RHEA-AI

neutral

06/07/22 7:00 AM

Nasdaq : KRYS

conferenceslow float

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, California. Krish

RHEA-AI

neutral

05/19/22 7:30 PM

Nasdaq : KRYS

conferencesclinical triallow float

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene

RHEA-AI

neutral

05/09/22 4:15 PM

Nasdaq : KRYS

earningslow float

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022 FDA allows dosing at a patient’s home in the Open Label Extension Study of B-VEC for the treatment of DEB Positive Clinical Phase 1 (Pearl-1 Study)

RHEA-AI

neutral

05/03/22 7:00 AM

Nasdaq : KRYS

conferenceslow float

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare

RHEA-AI

neutral

04/11/22 7:00 AM

Nasdaq : KRYS

low float

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study

Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, the

RHEA-AI

neutral

03/28/22 11:00 AM

Nasdaq : KRYS

clinical triallow float

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine

Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared with placebo with minimal

RHEA-AI

neutral

1 2 3 4 5 6 Next